JAZF1, a transcriptional repressor linked to metabolic regulation (Rosario et al., 2023) and cellular proliferation (Sung et al., 2018), has been implicated in both type 2 diabetes and PCa risk through GWAS (Machiela et al., 2012; Sánchez-Maldonado et al., 2022). Here, JAZF1 is linked to type 2 diabetes mellitus.